4,843 Shares in Revvity, Inc. (NYSE:RVTY) Acquired by Raymond James Financial Services Advisors Inc.

Raymond James Financial Services Advisors Inc. purchased a new position in Revvity, Inc. (NYSE:RVTY) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 4,843 shares of the company’s stock, valued at approximately $529,000.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Gladius Capital Management LP grew its stake in shares of Revvity by 84.1% during the 3rd quarter. Gladius Capital Management LP now owns 232 shares of the company’s stock worth $26,000 after purchasing an additional 106 shares during the period. JTC Employer Solutions Trustee Ltd acquired a new stake in shares of Revvity during the 4th quarter worth approximately $33,000. Headinvest LLC acquired a new stake in shares of Revvity during the 3rd quarter worth approximately $57,000. DB Wealth Management Group LLC acquired a new stake in shares of Revvity during the 4th quarter worth approximately $79,000. Finally, Sugarloaf Wealth Management LLC acquired a new stake in shares of Revvity during the 4th quarter worth approximately $168,000. Institutional investors and hedge funds own 86.65% of the company’s stock.

Revvity Stock Down 1.2 %

Shares of NYSE:RVTY opened at $99.33 on Friday. The business has a 50-day moving average price of $104.83 and a 200 day moving average price of $101.69. The company has a current ratio of 2.07, a quick ratio of 1.77 and a debt-to-equity ratio of 0.40. The company has a market capitalization of $12.27 billion, a price-to-earnings ratio of 18.06, a PEG ratio of 2.61 and a beta of 1.09. Revvity, Inc. has a 12-month low of $79.50 and a 12-month high of $135.88.

Revvity (NYSE:RVTY) last issued its quarterly earnings data on Thursday, February 1st. The company reported $1.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.15 by $0.10. The firm had revenue of $695.90 million during the quarter. Revvity had a return on equity of 7.41% and a net margin of 25.20%. Sell-side analysts expect that Revvity, Inc. will post 4.65 EPS for the current year.

Revvity Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, May 10th. Shareholders of record on Friday, April 19th will be given a $0.07 dividend. This represents a $0.28 annualized dividend and a yield of 0.28%. The ex-dividend date is Thursday, April 18th. Revvity’s dividend payout ratio is currently 5.09%.

Analyst Ratings Changes

A number of equities research analysts have recently commented on RVTY shares. Raymond James raised their price objective on shares of Revvity from $106.00 to $127.00 and gave the stock an “outperform” rating in a research note on Friday, February 2nd. Evercore ISI upgraded Revvity from an “in-line” rating to an “outperform” rating and increased their target price for the company from $88.00 to $125.00 in a research report on Thursday, January 4th. KeyCorp increased their target price on Revvity from $110.00 to $126.00 and gave the company an “overweight” rating in a research report on Friday, February 2nd. UBS Group lowered Revvity from a “buy” rating to a “neutral” rating and increased their target price for the company from $105.00 to $125.00 in a research report on Tuesday, January 16th. Finally, Barclays increased their target price on Revvity from $92.00 to $105.00 and gave the company an “equal weight” rating in a research report on Thursday, January 25th. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $118.91.

Insider Buying and Selling at Revvity

In other Revvity news, insider Prahlad R. Singh sold 21,217 shares of Revvity stock in a transaction dated Monday, February 5th. The stock was sold at an average price of $104.28, for a total value of $2,212,508.76. Following the completion of the transaction, the insider now directly owns 92,801 shares of the company’s stock, valued at approximately $9,677,288.28. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.60% of the stock is currently owned by corporate insiders.

About Revvity

Revvity, Inc provides health sciences solutions, technologies, and services in the Americas, Europe, and Asia, and internationally. The Life Sciences segment provides instruments, reagents, informatics, software, subscriptions, detection, imaging technologies, warranties, training, and services. Its Diagnostics segment provides instruments, reagents, assay platforms, and software products for the early detection of genetic disorders, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market.